Frida Rosenblum
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Frida Rosenblum has a total of 78 co-authors. Here are the top co-authors by number of shared publications:
- Abolfazl Zarjou
Division of Nephrology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294, USA
1 shared publication Afonso Santos
Department of Nephrology, Hospital Fernando Fonseca, Lisbon, Portugal; and
1 shared publication- Aishwarya Ravindran
Department of Pathology, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, AL
1 shared publication Ali M. Ahmed
University of Alabama at Birmingham, Division of Gastroenterology and Hepatology
1 shared publication- Andrea Angioi
Nephrology, Dialysis and Transplantation Unit, “Giuseppe Brotzu” Hospital (ARNAS G. Brotzu), Cagliari, Italy
1 shared publication Andrea Gersztein
Servicios Centrales de diagnóstico y Tratamiento Hospital General de Agudos “Carlos G. Durand” Buenos Aires Argentina
1 shared publication
Latest Publications
- 30 April 2026
- Published by Wiley in Cytopathology
- Vol. 37 (5) , 472-484
Role of Scientific Societies in Continuing Education in Cytopathology: Present and Future Perspectives
This article analyzes the role of Scientific Medical Societies (SMS) in continuing education in Cytopathology, emphasizing their impact on professional development, diagnostic quality, and patient safety. In recent years, Cytopathology has undergone significant growth driven by technological and molecular advances, which have expanded its scope and complexity. In this context, SMS play a crucial role by offering training activities such as congresses, courses, workshops, and publications, acting as a bridge between scientific evidence and clinical practice. The article also addresses current challenges related to equitable access, pedagogical innovation, and the integration of new technologies, as well as potential strategies for strengthening continuing education and international cooperation.
- 30 April 2026
- Published by Wiley in Cytopathology
- Vol. 37 (5) , 472-484
Role of Scientific Societies in Continuing Education in Cytopathology: Present and Future Perspectives
This article analyzes the role of Scientific Medical Societies (SMS) in continuing education in Cytopathology, emphasizing their impact on professional development, diagnostic quality, and patient safety. In recent years, Cytopathology has undergone significant growth driven by technological and molecular advances, which have expanded its scope and complexity. In this context, SMS play a crucial role by offering training activities such as congresses, courses, workshops, and publications, acting as a bridge between scientific evidence and clinical practice. The article also addresses current challenges related to equitable access, pedagogical innovation, and the integration of new technologies, as well as potential strategies for strengthening continuing education and international cooperation.
- Top Cited PapersOpen Access
- 26 February 2026
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 11 (8)
Macrophage ferritin heavy chain/α-synuclein regulatory axis modulates ferroptosis during kidney injury
Macrophages, endowed with remarkable phenotypic plasticity, are essential for orchestrating injury responses and regulating iron homeostasis. Given the central role of ferritin heavy chain (FtH) as a molecular rheostat linking iron sequestration to redox-dependent signaling, we examined how myeloid FtH governs renal iron trafficking and ensuing oxidative stress pathways during acute kidney injury (AKI). Transcriptome analysis revealed coupling of FtH deficiency in monocytes and macrophages with activation of ferroptosis, a regulated cell death associated with iron accumulation. Moreover, myeloid FtH deletion worsened AKI, increasing leukocyte infiltration and iron deposition, together with ferroptosis-associated gene induction, oxidative stress, and lipid peroxidation. Notably, α-synuclein (SNCA), an iron-binding protein and the main pathological driver of Parkinson’s disease, was robustly induced both by FtH deficiency and following AKI. Mechanistic studies showed that monomeric SNCA exhibits ferrireductase activity, amplifying redox cycling and promoting ferroptotic cell death. Furthermore, SNCA expression was elevated in kidney pathologies characterized by leukocyte expansion in both mouse models and human cohorts, suggesting that inflammatory microenvironments promote SNCA accumulation and redox imbalance. These findings define a macrophage FtH/SNCA regulatory axis as a key driver of ferroptosis in AKI, implicating SNCA as a pathological nexus between iron dyshomeostasis and inflammatory kidney injury.
- 26 February 2026
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 11 (8)
Top Cited PapersOpen AccessMacrophage ferritin heavy chain/α-synuclein regulatory axis modulates ferroptosis during kidney injury
Macrophages, endowed with remarkable phenotypic plasticity, are essential for orchestrating injury responses and regulating iron homeostasis. Given the central role of ferritin heavy chain (FtH) as a molecular rheostat linking iron sequestration to redox-dependent signaling, we examined how myeloid FtH governs renal iron trafficking and ensuing oxidative stress pathways during acute kidney injury (AKI). Transcriptome analysis revealed coupling of FtH deficiency in monocytes and macrophages with activation of ferroptosis, a regulated cell death associated with iron accumulation. Moreover, myeloid FtH deletion worsened AKI, increasing leukocyte infiltration and iron deposition, together with ferroptosis-associated gene induction, oxidative stress, and lipid peroxidation. Notably, α-synuclein (SNCA), an iron-binding protein and the main pathological driver of Parkinson’s disease, was robustly induced both by FtH deficiency and following AKI. Mechanistic studies showed that monomeric SNCA exhibits ferrireductase activity, amplifying redox cycling and promoting ferroptotic cell death. Furthermore, SNCA expression was elevated in kidney pathologies characterized by leukocyte expansion in both mouse models and human cohorts, suggesting that inflammatory microenvironments promote SNCA accumulation and redox imbalance. These findings define a macrophage FtH/SNCA regulatory axis as a key driver of ferroptosis in AKI, implicating SNCA as a pathological nexus between iron dyshomeostasis and inflammatory kidney injury.
- Open Access
- 26 February 2025
- Published by Wolters Kluwer Health in ACG Case Reports Journal
- Vol. 12 (3) , e01627
A Pelvic Mass in a Young Patient With Crohn's Disease
Castleman disease (CD) is a rare group of lymphoproliferative disorders subdivided based on clinical features. Although not fully understood, the pathogenesis of both CD and Crohn's disease involves a combination of immune dysregulation and infectious and environmental factors. Interleukin-6, a proinflammatory cytokine, is associated with both diseases and can serve as a common therapeutic target in CD. We report a rare case of coexisting unicentric Castleman disease in a young patient with Crohn's disease.
- 26 February 2025
- Published by Wolters Kluwer Health in ACG Case Reports Journal
- Vol. 12 (3) , e01627
Open AccessA Pelvic Mass in a Young Patient With Crohn's Disease
Castleman disease (CD) is a rare group of lymphoproliferative disorders subdivided based on clinical features. Although not fully understood, the pathogenesis of both CD and Crohn's disease involves a combination of immune dysregulation and infectious and environmental factors. Interleukin-6, a proinflammatory cytokine, is associated with both diseases and can serve as a common therapeutic target in CD. We report a rare case of coexisting unicentric Castleman disease in a young patient with Crohn's disease.
- 24 January 2022
- Published by Wiley in Cytopathology
- Vol. 33 (4) , 534-539
Fine needle aspiration of hepatic angiomyolipoma with extramedullary hematopoiesis: A case report
Angiomyolipoma, a perivascular epithelioid cell tumour, is easily identifiable as a benign tumour in the kidneys. However, when occurring in extrarenal sites it can mimic malignancy (Cancer Cytopathol. 2017;125:257). Pathologists must be aware of the classical morphological features of this lesion, its pitfalls in extrarenal sites, and the need for immunohistochemistry in order to establish the correct diagnosis (World J Gastroenterol. 2000;6:608). We report a case of angiomyolipoma with extramedullary hematopoiesis presenting as a large hepatic mass, diagnosed by cytology through endoscopic ultrasound guided fine needle aspiration. Our case exemplifies the classic cytological findings that are important in the differentiation between hepatic angiomyolipoma (HAML) and differentials in this organ such as hepatocellular carcinoma (HCC) and focal nodular hyperplasia. A brief literature review and comparison of significant features between HAML and HCC are presented.
- 24 January 2022
- Published by Wiley in Cytopathology
- Vol. 33 (4) , 534-539
Fine needle aspiration of hepatic angiomyolipoma with extramedullary hematopoiesis: A case report
Angiomyolipoma, a perivascular epithelioid cell tumour, is easily identifiable as a benign tumour in the kidneys. However, when occurring in extrarenal sites it can mimic malignancy (Cancer Cytopathol. 2017;125:257). Pathologists must be aware of the classical morphological features of this lesion, its pitfalls in extrarenal sites, and the need for immunohistochemistry in order to establish the correct diagnosis (World J Gastroenterol. 2000;6:608). We report a case of angiomyolipoma with extramedullary hematopoiesis presenting as a large hepatic mass, diagnosed by cytology through endoscopic ultrasound guided fine needle aspiration. Our case exemplifies the classic cytological findings that are important in the differentiation between hepatic angiomyolipoma (HAML) and differentials in this organ such as hepatocellular carcinoma (HCC) and focal nodular hyperplasia. A brief literature review and comparison of significant features between HAML and HCC are presented.
- 12 September 2021
- Published by Wiley in Hematological Oncology
- Vol. 39 (5) , 674-679
Secondary primary malignancies in patients with multiple myeloma: A single institution experience
The purpose of our study is to highlight the demographic characteristics, pathological features, and clinical course of multiple myeloma (MM) patients with secondary primary malignancies (SPM). A retrospective chart review was performed from January 2009 to February 2020. Patients' demographic, pathologic and cytogenetic features, treatment characteristics and clinical outcomes were collected. We identified 871 MM patients including 40 patients who developed SPM. Among the 40 patients with SPM, 17 patients developed hematological SPM and 23 patients developed solid SPM. The median time from diagnosis of MM to the occurrence of hematological SPM was 6.85 versus 3.91 years in solid SPM, with a median overall survival (OS) after diagnosis of SPM of 120 and 880 days, respectively. Interestingly, we observed that there was no significant difference in OS between MM patients with or without SPM. Multivariable analysis showed that age and autologous stem cell transplantation were independent factors associated with patients' clinical outcomes. Our study highlights the importance of understanding the etiology, biology, clinical outcome and management in MM patients with SPM.
- 12 September 2021
- Published by Wiley in Hematological Oncology
- Vol. 39 (5) , 674-679
Secondary primary malignancies in patients with multiple myeloma: A single institution experience
The purpose of our study is to highlight the demographic characteristics, pathological features, and clinical course of multiple myeloma (MM) patients with secondary primary malignancies (SPM). A retrospective chart review was performed from January 2009 to February 2020. Patients' demographic, pathologic and cytogenetic features, treatment characteristics and clinical outcomes were collected. We identified 871 MM patients including 40 patients who developed SPM. Among the 40 patients with SPM, 17 patients developed hematological SPM and 23 patients developed solid SPM. The median time from diagnosis of MM to the occurrence of hematological SPM was 6.85 versus 3.91 years in solid SPM, with a median overall survival (OS) after diagnosis of SPM of 120 and 880 days, respectively. Interestingly, we observed that there was no significant difference in OS between MM patients with or without SPM. Multivariable analysis showed that age and autologous stem cell transplantation were independent factors associated with patients' clinical outcomes. Our study highlights the importance of understanding the etiology, biology, clinical outcome and management in MM patients with SPM.
- 28 October 2020
- Published by Oxford University Press (OUP) in American Journal of Clinical Pathology
- Vol. 154 (Supplement) , S153
B-Cell/Mixed Phenotype Acute Leukemia Following Lenalidomide Maintenance For Multiple Myeloma: A Study Of Two Cases
Introduction/Objective The incidence of patients with multiple myeloma (MM) followed by hematologic malignancies as second primary malignancy is around 0.8 – 3.1%. The majority of cases are myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), however, acute lymphoblastic or mixed phenotype leukemia can be rarely observed. Methods A retrospective chart review was performed for patients diagnosed with acute lymphoblastic or mixed phenotype leukemia from January 2009 through February 2020. Two patients were identified and the corresponding clinical data were reviewed. Results Case 1 was a 74-year old male diagnosed with pre-B ALL 5 years after an IgG Lambda MM. His MM therapy included Bortezomib-based chemotherapy followed by Lenalidomide maintenance. Pre-B diagnosis was confirmed on a pelvic lesion biopsy with sheets of intermediate sized cells (CD45+, PAX5+, CD34+, CD43+, CD10+, BCL6+ and BCL2+). The patient had 4 cycles of HyperCVAD chemotherapy, followed by Blinatumomab and Inotuzumab treatment. Unfortunately, the patient was referred to hospice 2 years after the diagnosis of ALL. Case 2 was a 69-year old male diagnosed with mixed phenotype acute leukemia 8 years after an lgA Lambda MM with del 13q and Trisomy 11. The patient was treated with Bortezomib-based chemotherapy followed by autologous hematopoietic stem cell transplantation (auto-HSCT) and Lenalidomide maintenance. Bone marrow biopsy showed around 79% blasts (CD34+, PAX-5+, CD79a+ and MPO+). Flow cytometry from bone marrow showed 90% precursor B cells, however MPO was negative. Furthermore, a DNTM3A p.T835M missense variant (25-30% fraction) was identified by next generation sequencing (NGS). The patient was scheduled for Hyper-CVAD chemotherapy. Conclusion Lenalidomide maintenance following auto-HSCT is considered a standard therapy for MM patients. Recent studies indicate that Lenalidomide maintenance is associated with an increased risk of second primary hematologic malignancies. Although AML and MDS are more commonly seen, ALL and rarely mixed phenotype leukemias can occur.
- 28 October 2020
- Published by Oxford University Press (OUP) in American Journal of Clinical Pathology
- Vol. 154 (Supplement) , S153
B-Cell/Mixed Phenotype Acute Leukemia Following Lenalidomide Maintenance For Multiple Myeloma: A Study Of Two Cases
Introduction/Objective The incidence of patients with multiple myeloma (MM) followed by hematologic malignancies as second primary malignancy is around 0.8 – 3.1%. The majority of cases are myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), however, acute lymphoblastic or mixed phenotype leukemia can be rarely observed. Methods A retrospective chart review was performed for patients diagnosed with acute lymphoblastic or mixed phenotype leukemia from January 2009 through February 2020. Two patients were identified and the corresponding clinical data were reviewed. Results Case 1 was a 74-year old male diagnosed with pre-B ALL 5 years after an IgG Lambda MM. His MM therapy included Bortezomib-based chemotherapy followed by Lenalidomide maintenance. Pre-B diagnosis was confirmed on a pelvic lesion biopsy with sheets of intermediate sized cells (CD45+, PAX5+, CD34+, CD43+, CD10+, BCL6+ and BCL2+). The patient had 4 cycles of HyperCVAD chemotherapy, followed by Blinatumomab and Inotuzumab treatment. Unfortunately, the patient was referred to hospice 2 years after the diagnosis of ALL. Case 2 was a 69-year old male diagnosed with mixed phenotype acute leukemia 8 years after an lgA Lambda MM with del 13q and Trisomy 11. The patient was treated with Bortezomib-based chemotherapy followed by autologous hematopoietic stem cell transplantation (auto-HSCT) and Lenalidomide maintenance. Bone marrow biopsy showed around 79% blasts (CD34+, PAX-5+, CD79a+ and MPO+). Flow cytometry from bone marrow showed 90% precursor B cells, however MPO was negative. Furthermore, a DNTM3A p.T835M missense variant (25-30% fraction) was identified by next generation sequencing (NGS). The patient was scheduled for Hyper-CVAD chemotherapy. Conclusion Lenalidomide maintenance following auto-HSCT is considered a standard therapy for MM patients. Recent studies indicate that Lenalidomide maintenance is associated with an increased risk of second primary hematologic malignancies. Although AML and MDS are more commonly seen, ALL and rarely mixed phenotype leukemias can occur.
- Open Access
- 21 May 2020
- Published by American Society of Hematology in Blood
- Vol. 135 (21) , 1833-1846
Clinicopathologic predictors of renal outcomes in light chain cast nephropathy: a multicenter retrospective study
Light chain cast nephropathy (LCCN) in multiple myeloma often leads to severe and poorly reversible acute kidney injury. Severe renal impairment influences the allocation of chemotherapy and its tolerability; it also affects patient survival. Whether renal biopsy findings add to the clinical assessment in predicting renal and patient outcomes in LCCN is uncertain. We retrospectively reviewed clinical presentation, chemotherapy regimens, hematologic response, and renal and patient outcomes in 178 patients with biopsy-proven LCCN from 10 centers in Europe and North America. A detailed pathology review, including assessment of the extent of cast formation, was performed to study correlations with initial presentation and outcomes. Patients presented with a mean estimated glomerular filtration rate (eGFR) of 13 ± 11 mL/min/1.73 m2, and 82% had stage 3 acute kidney injury. The mean number of casts was 3.2/mm2 in the cortex. Tubulointerstitial lesions were frequent: acute tubular injury (94%), tubulitis (82%), tubular rupture (62%), giant cell reaction (60%), and cortical and medullary inflammation (95% and 75%, respectively). Medullary inflammation, giant cell reaction, and the extent of cast formation correlated with eGFR value at LCCN diagnosis. During a median follow-up of 22 months, mean eGFR increased to 43 ± 30 mL/min/1.73 m2. Age, β2-microglobulin, best hematologic response, number of cortical casts per square millimeter, and degree of interstitial fibrosis/tubular atrophy (IFTA) were independently associated with a higher eGFR during follow-up. This eGFR value correlated with overall survival, independently of the hematologic response. This study shows that extent of cast formation and IFTA in LCCN predicts the quality of renal response, which, in turn, is associated with overall survival.
- 21 May 2020
- Published by American Society of Hematology in Blood
- Vol. 135 (21) , 1833-1846
Open AccessClinicopathologic predictors of renal outcomes in light chain cast nephropathy: a multicenter retrospective study
Light chain cast nephropathy (LCCN) in multiple myeloma often leads to severe and poorly reversible acute kidney injury. Severe renal impairment influences the allocation of chemotherapy and its tolerability; it also affects patient survival. Whether renal biopsy findings add to the clinical assessment in predicting renal and patient outcomes in LCCN is uncertain. We retrospectively reviewed clinical presentation, chemotherapy regimens, hematologic response, and renal and patient outcomes in 178 patients with biopsy-proven LCCN from 10 centers in Europe and North America. A detailed pathology review, including assessment of the extent of cast formation, was performed to study correlations with initial presentation and outcomes. Patients presented with a mean estimated glomerular filtration rate (eGFR) of 13 ± 11 mL/min/1.73 m2, and 82% had stage 3 acute kidney injury. The mean number of casts was 3.2/mm2 in the cortex. Tubulointerstitial lesions were frequent: acute tubular injury (94%), tubulitis (82%), tubular rupture (62%), giant cell reaction (60%), and cortical and medullary inflammation (95% and 75%, respectively). Medullary inflammation, giant cell reaction, and the extent of cast formation correlated with eGFR value at LCCN diagnosis. During a median follow-up of 22 months, mean eGFR increased to 43 ± 30 mL/min/1.73 m2. Age, β2-microglobulin, best hematologic response, number of cortical casts per square millimeter, and degree of interstitial fibrosis/tubular atrophy (IFTA) were independently associated with a higher eGFR during follow-up. This eGFR value correlated with overall survival, independently of the hematologic response. This study shows that extent of cast formation and IFTA in LCCN predicts the quality of renal response, which, in turn, is associated with overall survival.
- 27 July 2017
- Published by Wiley in Diagnostic Cytopathology
- Vol. 45 (12) , 1142-1147
Fine‐needle aspiration findings of a rare hematopoietic neoplasm presenting as obstructive jaundice
A 51‐year‐old female who presented with obstructive jaundice was found to have masses in the pancreatic head and tail as well as suspicious liver and periaortic masses on imaging. Aspiration cytology of the pancreatic tail mass showed abundant large single cells with vacuolated eosinophilic cytoplasm, marked nuclear pleomorphism, large bizarre irregular nuclei, binucleation, and prominent nucleoli. Numerous cells also showed intracytoplasmic black to brown pigmentation. A cell block was obtained and extensive immunohistochemical staining was performed. S‐100, HMB‐45, Sox10, pancytokeratin, CK7, RCC antigen, synaptophysin, HepPar 1, inhibin, CD45, CD21, and CD123 were negative, making melanoma, epithelial malignancies, lymphoma, follicular dendritic and plasmacytoid dendritic cell neoplasms less likely. CD4 and CD56 showed partial positivity, and CD68, CD163, and CD14 were positive, supporting the diagnosis of histiocytic sarcoma. Surgical specimens and immunohistochemistry confirmed the cytologic findings. Histiocytic sarcoma is a rare aggressive malignancy of histiocytic origin with most cases presenting in adults in extranodal sites, most commonly the intestinal tract. Few cases are reported in the literature, presenting diagnostic challenges for cytopathologists when seen on fine‐needle aspiration. We present the first reported case of histiocytic sarcoma presenting as a pancreatic mass, diagnosed by endoscopic ultrasound guided fine‐needle aspiration (EUS‐FNA). This entity is rarely described on cytology and arose in a location in which EUS‐FNA is the diagnostic modality of choice. This case study highlights that cytopathologists should be aware of histiocytic sarcoma occurring in extranodal locations accessible by EUS‐FNA and be familiar with the cytomorphologic appearance.
- 27 July 2017
- Published by Wiley in Diagnostic Cytopathology
- Vol. 45 (12) , 1142-1147
Fine‐needle aspiration findings of a rare hematopoietic neoplasm presenting as obstructive jaundice
A 51‐year‐old female who presented with obstructive jaundice was found to have masses in the pancreatic head and tail as well as suspicious liver and periaortic masses on imaging. Aspiration cytology of the pancreatic tail mass showed abundant large single cells with vacuolated eosinophilic cytoplasm, marked nuclear pleomorphism, large bizarre irregular nuclei, binucleation, and prominent nucleoli. Numerous cells also showed intracytoplasmic black to brown pigmentation. A cell block was obtained and extensive immunohistochemical staining was performed. S‐100, HMB‐45, Sox10, pancytokeratin, CK7, RCC antigen, synaptophysin, HepPar 1, inhibin, CD45, CD21, and CD123 were negative, making melanoma, epithelial malignancies, lymphoma, follicular dendritic and plasmacytoid dendritic cell neoplasms less likely. CD4 and CD56 showed partial positivity, and CD68, CD163, and CD14 were positive, supporting the diagnosis of histiocytic sarcoma. Surgical specimens and immunohistochemistry confirmed the cytologic findings. Histiocytic sarcoma is a rare aggressive malignancy of histiocytic origin with most cases presenting in adults in extranodal sites, most commonly the intestinal tract. Few cases are reported in the literature, presenting diagnostic challenges for cytopathologists when seen on fine‐needle aspiration. We present the first reported case of histiocytic sarcoma presenting as a pancreatic mass, diagnosed by endoscopic ultrasound guided fine‐needle aspiration (EUS‐FNA). This entity is rarely described on cytology and arose in a location in which EUS‐FNA is the diagnostic modality of choice. This case study highlights that cytopathologists should be aware of histiocytic sarcoma occurring in extranodal locations accessible by EUS‐FNA and be familiar with the cytomorphologic appearance.
- 9 March 2017
- Published by Wiley in Diagnostic Cytopathology
- Vol. 45 (7) , 634-639
An adolescent with large cell calcifying sertoli cell tumor of the testis and undiagnosed Carney Complex: A case report
Carney Complex (CNC) is a rare autosomal dominant condition with characteristic clinical presentation, tumor development, and unique genetic mutation. We present a unique case and literature review of CNC in which two neoplasms characteristic of this complex were initially diagnosed through cytological fine needle aspirate specimens, leading to the identification of CNC, with subsequent surgical and cytogenetic confirmation. Diagn. Cytopathol. 2017;45:634–639.
- 9 March 2017
- Published by Wiley in Diagnostic Cytopathology
- Vol. 45 (7) , 634-639
An adolescent with large cell calcifying sertoli cell tumor of the testis and undiagnosed Carney Complex: A case report
Carney Complex (CNC) is a rare autosomal dominant condition with characteristic clinical presentation, tumor development, and unique genetic mutation. We present a unique case and literature review of CNC in which two neoplasms characteristic of this complex were initially diagnosed through cytological fine needle aspirate specimens, leading to the identification of CNC, with subsequent surgical and cytogenetic confirmation. Diagn. Cytopathol. 2017;45:634–639.